Mauro Maccarrone

@univaq.it

Professor and Chair, Department of Biotechnological and Applied Clinical Sciences
Università degli Studi dell'Aquila

Mauro Maccarrone


            Download Compact PDF  
https://researchid.co/k-5398-2012
Is Professor and Chair of Biochemistry at the Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila (Italy). He is also Head of the Lipid Neurochemistry Unit at the European Center for Brain Research – IRCCS Santa Lucia Foundation, Rome. For his research activity he has received the “4th Royan International Research Award for Reproductive Biomedicine” (2003), the “2007 IACM (International Association for Cannabis as Medicine) Award for Basic Research”, the “2016 Mechoulam Award”, the “2020 Tu Youyou Award”, and the “2020 International Space Station Research and Development Award” by the American Astronautical Society with NASA and CASIS. Chair of the 2015 Gordon Research Conference on “Cannabinoid Function in the CNS”. Visiting Professor at Leiden University (Leiden Institute of Chemistry, The Netherlands) in 2017, and at University of Cambridge (Department of Psychology, U.K.) in 2019.

EDUCATION

University of L’Aquila (I) M.S. in Biological Sciences (Biochemistry) - 1986
Universities of L’Aquila (I), of Chieti (I) and of Rome Tor Vergata (I) Ph.D. in Enzymology Applied to Medical Sciences - 1990
University of Utrecht (NL) Ph.D. in Bio-Organic Chemistry - 1992

RESEARCH INTERESTS

Bioactive lipids
Endocannabinoids
Proresolving lipid mediators
Signal transduction
590

Scopus Publications

Scopus Publications

Publications

Published more than 520 full papers, of which 65 with I.F. ≥ 9, 15 with I.F. ≥ 15, 65 with 100 - 475 citations (total I.F. > 2700; citations = 20795, h-index = 76 according to Scopus), including more than 45 review articles and more than 60 invited papers in international refereed journals, be-sides more than 100 mini-papers and more than 330 Congress communications. Among others, he published 14 papers in J. Biol. Chem., 10 in J. Neurosci., 9 in Cell. Mol. Life Sci., 8 in Cell Death Differ., 6 in Trends Pharmacol. Sci., 4 in Blood, Neuropsychopharmacol. and FASEB J., 3 in Prog. Lipid Res., Biol. Psych. and J. Immunol., 2 in Prog. Neurobiol., Nature Commun., PNAS, Ann. Neurol. and Brain, 1 in NEJM, Nature Rev. Neurosci., Science, Science Trans. Med., Lancet, Lancet Neurol., JAMA, Endocr. Rev., Nature Neurosci., Trends Biochem. Sci., Annu. Rev. Nutr., and Gastroenterology.
Due to his scientific activity and impact, is included by Stanford University in the “2021 World Top 2% Scientists' List”, where he holds the 179th position among 4955 Italian researchers. He is also listed among the “Top Italian Scientists”.

GRANT DETAILS

a. MoMa Project of the Italian Space Agency (ASI-ESA-NASA) 2006 – The endocannabinoid system in the induction of T cell apoptosis un-der microgravity conditions. Local PI. DCMC Project of the Italian Space Agency (ASI-ESA-NASA) 2006 – The endocannabinoid system in the control of neuronal cell death under microgravity conditions. Local PI.
b. Research Project HIGH Q FOUNDATION Inc. (New Jersey, U.S.A.) 2007 – Endocannabinoid system as potential biomarker and therapeu-tic target in HD. PI.
c. Research Project NATIONAL INSTITUTES OF HEALTH (NIH) 2007 – Characterization of anandamide transport in brain (subaward No. 2007-1917 under NIH prime award No. DA012413). Local PI.
d. Research Project of National Interest (PRIN) 2008 - Interaction of anandamide hydrolase (FAAH) with membranes: how to get hydropho-bic substrates and release hydrophilic products. PI.
e. Medical Research Council (MRC)-funded research 2009-2011 –The endocannabinoid, anandamide as a biomarker of outcome in preg-nancies complicated by threatened miscarriage. Local PI.
f. L’Oreal (Paris) 2009-2012 - Endocannabinoid system in melanocytes: A target for novel cosmetic drugs. PI.
g. SIGMA TAU Industries (Rome) 2009-2010 – Study of potential reversible inhibitors of FAAH. PI.
h. GW Pharmaceuticals PLC (London) 2010-2011 - Regulation of gene expression through DNA methylation by cannabidiol and other phy-tocannabinoids. PI.
i. Fondazione Italiana Sclerosi Multipla 2010-2011 - Role of the endocannabinoid system in the n

RESEARCH OUTPUTS (PATENTS, SOFTWARE, PUBLICATIONS, PRODUCTS)

Holder of the following granted patents: 1) Enol carbamate derivatives as modulators of fatty acid amide hydrolase (TW200948805, AR072346). 2) Oxime carbamoyl derivatives as modulators of fatty acid amide hydrolase (WO2009138416, AR071800). 3) Compounds of 2,3-dihydro-4H-1,3-benzoxazine-4-one, method for preparing them and pharmaceutical form comprising them (WO2013IB61106, ITMI20122221). 4) Use of canna-binoid compounds for stimulating melanogenesis (FR2978659, 2014). 5) Use of a cb1 receptor antagonist as a whitening and/or anti-browning agent for keratin material (FR2978660, 2013). 6) Design and synthesis of biotinylated probes for n-acyl-ethanolamines (US7955816, 2011). 7) Method and kit for the early diagnosis of miscarriage in human beings (EP1272659, 2007). 8) Funzionalizzazione innovativa su sensori in fase liquida per la rilevazione di lipidi bioattivi (IT20180008035). 9) Metodo per la diagnosi della malattia di Huntington (IT0001378173).

CONSULTANCY

Consultant for different pharmaceutical companies, at the national (Dompè, Sigma-Tau, Vetagro, Angelini) and international level (Takeda Phar-maceutical Company, Reddy U.S. Therapeutics, GW Pharmaceuticals, Hoffmann-La Roche, Almirall, Phytecs, InMed Pharmaceuticals).